Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. cut its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 20.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 290,353 shares of the company’s stock after selling 72,595 shares during the quarter. Pacer Advisors Inc.’s holdings in Harmony Biosciences were worth $10,865,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of HRMY. EverSource Wealth Advisors LLC boosted its position in shares of Harmony Biosciences by 589.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares in the last quarter. Allworth Financial LP grew its stake in shares of Harmony Biosciences by 286.7% in the 4th quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after purchasing an additional 602 shares during the last quarter. Leonteq Securities AG bought a new stake in shares of Harmony Biosciences in the 4th quarter worth approximately $30,000. National Bank of Canada FI bought a new stake in shares of Harmony Biosciences in the 3rd quarter worth approximately $40,000. Finally, Clearstead Advisors LLC lifted its stake in Harmony Biosciences by 145.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after purchasing an additional 699 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $33.28 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.56 and a current ratio of 3.58. The company has a market cap of $1.93 billion, a PE ratio of 13.42, a price-to-earnings-growth ratio of 0.23 and a beta of 0.96. Harmony Biosciences Holdings, Inc. has a 52 week low of $25.52 and a 52 week high of $40.87. The firm has a 50 day simple moving average of $31.44 and a 200 day simple moving average of $33.06.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The firm had revenue of $215.39 million for the quarter, compared to analysts’ expectations of $220.84 million. During the same quarter in the previous year, the firm posted $0.78 earnings per share. The company’s revenue for the quarter was up 16.6% on a year-over-year basis. As a group, research analysts expect that Harmony Biosciences Holdings, Inc. will post 3.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HRMY. Deutsche Bank Aktiengesellschaft cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 target price for the company. in a report on Monday, February 23rd. UBS Group dropped their price target on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Zacks Research raised Harmony Biosciences from a “strong sell” rating to a “hold” rating in a research note on Friday, May 1st. Truist Financial lifted their target price on Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a report on Friday, May 8th. Finally, Needham & Company LLC cut their target price on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $40.89.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.